InvestSMART

Neurizon Therapeutics Limited (ASX: NUZ) - Announcements

- Current share price for NUZ : $0.075

ASX company news and announcements for Neurizon Therapeutics Limited (NUZ) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neurizon Therapeutics Limited (NUZ) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neurizon Therapeutics Limited (NUZ), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neurizon Therapeutics Limited (NUZ)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$59 Neurizon Secures Loan Against 2025 R&D Tax Rebate 30 Jul 2025 9:10AM $0.170 $0.075 fallen by 55.88%
$59 Neurizon Submits Clinical Hold Complete Response to FDA 25 Jul 2025 9:22AM $0.155 $0.075 fallen by 51.61%
$59 Positive feedback from FDA on strategy to lift clinical hold 10 Jul 2025 9:15AM $0.160 $0.075 fallen by 53.13%
$59 Presentation Materials - Licensing Agreement Webinar 2 Jul 2025 12:20PM $0.160 $0.075 fallen by 53.13%
$59 Invitation to Shareholder Webinar 2 Jul 2025 8:58AM $0.155 $0.075 fallen by 51.61%
$59 Neurizon Enters Global Licensing Agreement with Elanco 2 Jul 2025 8:49AM $0.155 $0.075 fallen by 51.61%
$59 Notification regarding unquoted securities - NUZ 26 Jun 2025 5:57PM $0.170 $0.075 fallen by 55.88%
$59 Neurizon develops liquid formulation of NUZ-001 26 Jun 2025 9:24AM $0.165 $0.075 fallen by 54.55%
$59 NUZ-001 Shows Significant Blood-Brain Barrier Penetration 20 Jun 2025 9:32AM $0.170 $0.075 fallen by 55.88%
$59 Release of Securities from Escrow 16 Jun 2025 7:12PM $0.165 $0.075 fallen by 54.55%
$59 NUZ-001 Shows Promise in a Model of Huntington's Disease 16 Jun 2025 9:32AM $0.160 $0.075 fallen by 53.13%
$59 Change of Registered Office and Principal Place of Business 2 Jun 2025 9:45AM $0.135 $0.075 fallen by 44.44%
$59 Neurizon to present at Annual ALS Drug Development Summit 14 May 2025 4:54PM $0.140 $0.075 fallen by 46.43%
$59 Neurizon to present Q3 FY2025 Results 6 May 2025 12:48PM $0.135 $0.075 fallen by 44.44%
$59 Last Patient Successfully Completes Treatment in OLE Study 5 May 2025 9:23AM $0.140 $0.075 fallen by 46.43%
$59 Appendix 4C & Quarterly Update 28 Apr 2025 9:11AM $0.120 $0.075 fallen by 37.50%
$59 Notice of Quarterly Shareholder Update Webinar 24 Apr 2025 9:28AM $0.125 $0.075 fallen by 40%
$59 Appointment of Chief Financial Officer 22 Apr 2025 9:28AM $0.120 $0.075 fallen by 37.50%
$59 Leadership team strengthened with strategic appointments 17 Apr 2025 9:22AM $0.100 $0.075 fallen by 25%
$59 NUZ-001 Promotes Survival in TDP-43 Challenged NSC-34 Cells 4 Apr 2025 12:07PM $0.115 $0.075 fallen by 34.78%
$59 NUZ-001 Shows Positive Results in Human 3D Brain Model 1 Apr 2025 9:03AM $0.130 $0.075 fallen by 42.31%
$59 NUZ-001 shows promising respiratory outcome 24 Mar 2025 9:47AM $0.110 $0.075 fallen by 31.82%
$59 Neurizon Commences Initiatives to Lift Clinical Hold 17 Mar 2025 9:22AM $0.110 $0.075 fallen by 31.82%
$59 Appendix 4D - Half-year Financial Report - 31 December 2024 17 Feb 2025 2:28PM $0.155 $0.075 fallen by 51.61%
$59 Neurizon to Present Latest Results and Key Updates 17 Feb 2025 9:27AM $0.130 $0.075 fallen by 42.31%

126 - 150 of 185 results

Page 6 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.